- Molecular NameAminophenazone
- Synonym4-Dimethylaminoantipyrine; Aminopyrine; Dipyrine
- Weight231.299
- Drugbank_IDDB01424
- ACS_NO58-15-1
- Show 2D model
- LogP (experiment)1.0
- LogP (predicted, AB/LogP v2.0)-0.52
- pka5.6
- LogD (pH=7, predicted)-0.53
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.76
- LogSw (predicted, AB/LogsW2.0)19.7
- Sw (mg/ml) (predicted, ACD/Labs)39.65
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds2
- TPSA26.79
- StatusFDA approved
- AdministrationN/A
- PharmacologyA pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of agranulocytosis.
- Absorption_value100.0
- Absorption (description)Absorbed after oral administration.
- Caco_2-4.44
- BioavailabilityN/A
- Protein binding27.5
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is rapidly and extensively metabolised.
- Half lifePlasma half-life, about 2 to 3 h
- ExcretionAbout 30 to 50% of a dose is excreted in the urine in 3 days as 4-aminophenazone and its acetyl derivative 4-acetamidophenazone which is the major urinary metabolite; other metabolites found in the urine include two red pigments, rubazonic acid and methylrubazonic acid; dimethylnitrosamine may be formed in the stomach. Less than 5% of a dose is excreted in the urine unchanged.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe use of aminophenazone is discouraged due to the risk of fatal agranulocytosis. The estimated minimum lethal dose is 5 g.
- LD50 (rat)N/A
- LD50 (mouse)N/A